Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Interim Report 1st Quarter 201111 May 2011
Genmab Announces Financial Results for the First Quarter 201111 May 2011
Arzerra first quarter 2011 net sales figures27 Apr 2011
Genmab Announces Appointment of Rachel Curtis Gravesen as New Head of Investor Relations27 Apr 2011
Articles of Association of Genmab A/S20 Apr 2011
Genmab and Seattle Genetics Expand Antibody-Drug Conjugate Collaboration19 Apr 2011
Articles of Association19 Apr 2011
Passing of Genmab A/S' Annual General Meeting
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
6 Apr 2011
Constitution of the Board of Directors in Genmab A/S and Grant of Warrants to a Board Member and Employees6 Apr 2011
Report Pursuant to Section 28a of the Danish Securities Trading Act6 Apr 2011
Genmab's Annual Report 201015 Mar 2011
Genmab A/S Summons Annual General Meeting15 Mar 2011
  • Previous
  • 1
  • More pages
  • 96
  • 97
  • 98
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863